Key Highlights

  • PhRMA sued on Oct. 7 in the US District Court for the District of Columbia to invalidate the GLOBE rule.
  • HHS now projects Medicare Part B savings of about USD 440 million over seven years, down from USD 11.9 billion.
  • The pricing regime may reach as few as four drugmakers once companies with White House deals are exempted.
  • The final rule, published last week, ties Part B drug prices to levels paid in comparable countries.

The Lawsuit Filed in Washington

The pharmaceutical industry's top lobby group sued on Wednesday to invalidate the Trump administration's effort to benchmark Medicare drug prices to lower costs overseas, arguing the move is an illegal government overreach. The Pharmaceutical Research and Manufacturers of America, known as PhRMA, filed the complaint in the US District Court for the District of Columbia.

The defendants are Health Secretary Robert F. Kennedy Jr., the Department of Health and Human Services he runs, the Centers for Medicare & Medicaid Services and two of its officials. Those named include CMS Administrator Dr. Mehmet Oz, the agency's innovation center, which runs the most-favored-nation pricing pilot, and the director of that division, Abe Sutton.

The challenge targets the GLOBE rule. Its final version, published last week, sets out how a "most-favored-nation" pricing system, based on what is paid in a group of comparable countries, would be built into the Medicare Part B program. Medicare is the federal program that provides health coverage to about 70 million people aged 65 and older or with disabilities.

A Dispute Over CMS Authority

PhRMA argues that CMS has stretched the authority of a program meant to test new pricing ideas into a rewrite of Medicare's pricing structure, without action by Congress. The group's general counsel said in an interview that Congress has given CMS "a little bit of authority to test models." He said CMS is "doing exactly what Congress has declined to do multiple times over the last several years, and that's to replace the pricing structure in Medicare with a most-favored-nation structure."

HHS was not immediately available to comment on the lawsuit. In the finalized rule, however, the agency argued that it was not overstepping its bounds, writing that "CMS is acting within a detailed, purpose specific statutory framework that Congress designed precisely for this type of model test."

PhRMA has been here before. In 2020 it successfully sued to block an earlier version of most-favored-nation pricing, but that rule was invalidated on procedural grounds because the administration had rushed it out without giving the public a chance to comment. The new complaint centers on whether the statute gives CMS the power to do what the rule describes.

A Rule With a Narrower Reach

The final rule reaches far fewer companies than the proposal. CMS plans to waive the requirement for manufacturers that have signed separate deals with the White House to take part in the price-setting model, according to the rule. President Donald Trump has already signed deals with more than two dozen drugmakers, including many of the world's largest, such as Pfizer, Eli Lilly and Novo Nordisk. After those exemptions, the pricing regime may ultimately apply to as few as four drugmakers.

The final rule also sharply reduced the government's projected savings. HHS now estimates the program lowers Medicare Part B spending by about USD 440 million over the seven-year model period, compared with roughly USD 11.9 billion projected in the proposed rule published last year.

Published legal and trade analyses of the final rule add detail. The model starts on Jan. 1, 2027, and covers Original Medicare Part B enrollees in selected areas that represent about 25% of Part B beneficiaries. Benchmarks draw on prices in 19 reference countries. The final rule also added exclusions for orphan-only drugs, plasma-derived products and certain cell and gene therapies, and it cut the number of affected manufacturers to about four from about 40 in the proposal.

Court Steps to Watch

The items to follow are the government's response to the complaint, any ruling on whether CMS acted within its model-testing authority, the Jan. 1, 2027 start date for the model, and the number of drugmakers that remain inside the rule after exemptions.